Vinva Investment Management Boosts Regeneron Pharmaceuticals Stake

Hedge fund increases holdings in biotech firm by over 30% in Q3

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Vinva Investment Management Ltd. raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 31.3% during the third quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 8,775 shares of the biopharmaceutical company's stock, valued at $4.92 million.

Why it matters

Regeneron is a major player in the biotech industry, known for its innovative drug discovery technologies and pipeline of biologic therapies. Institutional investors like Vinva closely monitor and adjust their positions in leading pharmaceutical companies, providing insights into market sentiment and potential growth opportunities.

The details

According to the 13F filing, Vinva Investment Management purchased an additional 2,093 shares of Regeneron Pharmaceuticals during the third quarter, increasing its total holdings to 8,775 shares. This represents a 31.3% increase in the firm's position compared to the prior quarter. Regeneron is a NASDAQ-listed biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for the treatment of serious medical conditions.

  • Vinva Investment Management filed its 13F report for the third quarter on 2026-03-09.

The players

Vinva Investment Management Ltd

A hedge fund that manages investments in various sectors, including the biopharmaceutical industry.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company that focuses on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Vinva's increased stake in Regeneron Pharmaceuticals suggests the hedge fund sees growth potential in the biotech firm's pipeline and market position. This is a positive signal for Regeneron's outlook, as institutional investors closely monitor and adjust their positions in leading pharmaceutical companies.